ImmunoGen Q4 Loss Widens; Sees FY15 Revenue Above View - Quick Facts

(RTTNews) - ImmunoGen, Inc. (IMGN), a developer of targeted anticancer therapeutics, Friday reported fourth-quarter net loss of $26.50 million or $0.31 per share, wider than $21.88 million or $0.26 per share in the prior year.

On average, 15 analysts polled by Thomson Reuters expected the company to report a loss of $0.32 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues increased to $5.74 million from $3.83 million a year ago. Analysts estimated revenues of $9.72 million for the quarter.

Total operating expenses advanced to $32.24 million from $25.77 million in the preceding year.

For fiscal 2015, ImmunoGen expects net loss to be in the range of $60 million to $65 million.

Revenues are expected to be between $100 million and $105 million. Analysts expect the company to report revenues of $70.60 million for the year.